Evolent Health (EVH) shares are soaring 7.19% in pre-market trading on Friday, as the company receives positive attention from Wall Street analysts. The healthcare technology firm's stock is gaining momentum following upbeat analyst reports and a price target increase.
UBS analyst Kevin Caliendo has raised the firm's price target on Evolent Health to $15 from $14, while maintaining a Buy rating on the shares. This upgrade represents increased confidence in the company's growth prospects and potential for value creation.
Additionally, TD Cowen analyst Charles Rhyee reaffirmed a Buy rating on Evolent Health, setting a price target of $14.00. The consistent positive sentiment from multiple analysts is likely contributing to investor enthusiasm and driving the stock's pre-market surge.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.